KLOW Stack Stack Protocol

Stack Overview

The KLOW Stack is the GLOW Stack (GHK-Cu + BPC-157 + TB-500) with KPV added as a dedicated anti-inflammatory leg. KPV — the C-terminal tripeptide fragment of α-MSH — is a specific inhibitor of NF-κB, the master transcription factor driving most pro-inflammatory cytokine output. Adding it to GLOW is the move you make when you suspect chronic low-grade inflammation is the rate-limiting factor on your repair response.

Who this is for: users with chronic inflammatory overlays on their repair goals — longstanding rosacea, atopic dermatitis, chronic tendinopathy that keeps flaring, IBD-spectrum gut issues combined with MSK injury, post-COVID chronic inflammation, autoimmune-adjacent skin conditions. Also users who ran GLOW and plateaued earlier than expected and suspect inflammation is why.

Who this is NOT for: same contraindications as GLOW plus anyone acutely immunosuppressed (KPV's anti-inflammatory action could compound). Active systemic infection. People running their first peptide stack — KLOW is a four-compound regimen, too many variables to isolate response. Start with Wolverine or GLOW, add KPV only if needed.

Honest framing: zero clinical trials on this four-peptide combination in humans. KPV individually has strong preclinical inflammation data but its oral and systemic use in humans is community-practice, not RCT. The stack is mechanistic rationale + individual-compound preclinical evidence + ~5 years of aggregated community experience with the specific combination.

The Compounds

Why they pair: inflammation is the thumb on the scale against repair. High NF-κB activity drains resources into cytokine production and keeps tissue in a pro-inflammatory state that opposes the matrix synthesis GHK-Cu stimulates, the angiogenesis BPC-157 drives, and the cell migration TB-500 enables. KPV pulls down NF-κB specifically, so the other three can do their work in a lower-inflammation environment. The stack logic is cover the inflammation axis (KPV) plus the three regenerative axes (matrix + vascular + cellular).

Synergy & Mechanism

• Inflammation axis (KPV) — NF-κB inhibition pulls down the transcriptional driver of pro-inflammatory cytokines. Acts upstream of most of the inflammatory mediators other peptides in the stack partially affect.
• Matrix axis (GHK-Cu) — Collagen, elastin, and GAG synthesis. Delivers copper to lysyl oxidase for cross-linking.
• Vascular axis (BPC-157) — VEGFR2-driven angiogenesis; local nitric oxide availability; cytoprotection.
• Cellular axis (TB-500) — G-actin sequestration enables controlled fibroblast, endothelial, and immune cell migration; anti-fibrotic bias.
• Non-overlapping mechanisms — Four compounds, four different primary mechanisms. Minimal redundancy, maximal coverage.
• Gut overlap — BPC-157 (gastric cytoprotection) + KPV (intestinal NF-κB) is a strong gut-inflammation combination. GLOW alone is weaker on gut-specific goals; KLOW adds that coverage.
• Skin overlap — GHK-Cu (matrix) + KPV (inflammation) is a strong combination for inflammatory skin conditions that GLOW's components address incompletely.

Dosing Protocol & Reconstitution

KLOW is almost always run as the pre-blended 80 mg vial. Two common configurations exist: 5:1:1:1 (50 mg GHK-Cu + 10 mg each BPC/TB/KPV) and 4:1:1:1 (40 mg GHK-Cu + 10 mg each — note this sums to 70 mg total if labeled "80 mg" it includes a fill buffer). The 5:1:1:1 version is more common. Always verify the ratio on the vial label before reconstituting.

Standard community protocol: 0.1 mL (10 units) SubQ daily from the 80 mg pre-blend reconstituted in 3 mL BAC. The 5:1:1:1 version delivers ~1.7 mg GHK-Cu + ~330 mcg each of BPC-157, TB-500, and KPV per injection. The 4:1:1:1 variant delivers slightly less GHK-Cu (~1.3 mg) but the same amount of each other peptide.

Why the 3 mL reconstitution is the KLOW convention: unlike GLOW (which typically uses 2 mL), KLOW vials have more total peptide mass (80 mg vs 70 mg), and the slightly larger volume keeps the per-injection dose at the community-standard 1.3–1.7 mg GHK-Cu range rather than driving it higher. Running KLOW in 2 mL would deliver ~2.5 mg GHK per 10 units, which is reasonable but higher than most users want for a four-compound daily protocol.

Adding oral KPV for gut-specific goals: KPV's oral bioavailability via the PepT1 transporter is the reason some users layer oral KPV on top of the injected KLOW blend. Typical oral dose is 200–500 mcg 1–3x daily with meals for IBD-spectrum or chronic gut-inflammation contexts.

Technique: 29G–31G insulin syringe. SubQ 45° into abdomen or thigh. Rotate sites. Verify the blue tint on reconstitution — the GHK-Cu complex must show. Refrigerated reconstituted solution, 28 days max.

→ Use the Kalios Peptide Calculator for exact syringe units

Sample Weekly Schedule

Standard 5 on / 2 off schedule using the 80 mg pre-blend (5:1:1:1) reconstituted in 3 mL BAC water (~26.7 mg/mL combined):

Total: 5 injections/week. Weekly totals: ~8.3 mg GHK-Cu + ~1.67 mg each of BPC-157, TB-500, KPV. One 80 mg vial lasts ~30 days at this cadence (0.5 mL/week drawn from 3 mL reconstituted).

Optional oral KPV add-on (for gut goals): 200 mcg oral KPV 1–2x daily with meals, Mon–Fri. Adds ~1–2 mg/week of gut-targeted anti-inflammatory activity. A separate 5 mg standalone KPV vial lasts ~4–6 weeks at this cadence.

Variant: 4:1:1:1 version. If using the 70 mg (40/10/10/10) variant instead of 5:1:1:1, the 10-unit dose delivers ~1.33 mg GHK-Cu with the same 333 mcg of each other peptide. Slightly less GHK-Cu per injection; same dosing schedule.

Cycle Structure & Timing

• Loading (weeks 1–6) — 5x/week injected. Pre-blend covers all four peptides. This is where inflammation should start coming down and remodeling should start coming up.
• Maintenance (weeks 7–12) — 3x/week injected. Remodeling phase with reduced inflammatory burden.
• Washout (weeks 13–16) — Minimum 4 weeks off. Particularly important for KLOW because of the broader gene-expression footprint of GHK-Cu plus the NF-κB suppression of KPV — you want to confirm the post-cycle baseline isn't hiding anything.
• Re-cycle — For chronic inflammatory conditions, 2–3 cycles per year is typical. Between cycles, lifestyle and nutritional anti-inflammatory support should carry the tone.
• Procedural timing (if cosmetic) — Same as GLOW: begin 1–2 weeks before planned microneedling / laser / peel; continue 8 weeks after for remodeling.
• Inflammatory-flare timing — Starting KLOW during an active flare is reasonable (that's when inflammation is worst and the stack is most needed). Starting during quiescence for prevention is also reasonable. Don't start during active infection — pause until resolved.

What to Expect — Timeline

• Week 1–2 — KPV often produces the earliest subjective change in this stack. Users with chronic inflammation (joint aches, gut cramping, skin redness) often report the first reduction in these within 5–10 days. Other benefits still latent.
• Week 3–4 — GHK-Cu skin effects become visible; BPC-157 local effects at injury sites mature; TB-500 systemic signal builds. Chronic inflammation usually meaningfully reduced.
• Week 5–8 — Primary response window. Multi-system benefits converge: skin quality, joint/tendon recovery, gut symptoms, mood (inflammation-mediated), energy. Users often describe this as the "all four are working" window.
• Week 9–12 — Consolidation. Peak gains. Hair responders see density changes; scar responders see softening; tendinopathy responders see load tolerance.
• Washout (13–16) — The honest post-cycle window. Skin, scar, matrix gains typically hold (structural remodeling). Anti-inflammatory benefits attenuate partially — chronic inflammation is lifestyle-driven, and once the KPV leg is off, some users see their baseline drift back if lifestyle hasn't changed.
• Gut-specific responders — IBD-spectrum users sometimes report the fastest and most dramatic response in this stack — KPV + BPC-157 is a potent gut combination mechanistically. Not a substitute for prescription IBD therapy, but a meaningful adjunct in some users.
• Non-responders — If week 6 has brought no changes across any of the four target axes (inflammation, skin, MSK, gut), this stack is unlikely to start working. Reassess baseline (product quality, technique, underlying condition) before escalating.

Side Effects & Monitoring

• Individual components — See GLOW Stack notes for GHK-Cu, BPC-157, TB-500. KPV additions below.
• KPV — Exceptionally well-tolerated in the available data. Occasional injection site itching. Rare reports of mild GI upset with high-dose oral use. No documented serious adverse events at community doses.
• Combined — No unique additive side effects identified. Theoretical concern is over-suppression of useful inflammation (e.g., needed for infection response). Practically not observed at KLOW doses.
• Masked infection — NF-κB suppression can blunt the signs of infection. Users should be attentive to low-grade illness symptoms and not assume "stack is working" masks a UTI, sinus infection, or similar.
• Copper balance — GHK-Cu is the same as in GLOW; same ceruloplasmin/serum-copper considerations on extended use.
• Angiogenesis / tumor concern — BPC-157 and TB-500 same concerns. KPV does not share this profile; GHK-Cu's pro-angiogenic signal is weaker than BPC-157's.
• Baseline monitoring — CMP + CBC, hsCRP (baseline inflammation), ferritin. For IBD-spectrum users, fecal calprotectin before and after cycle provides objective GI inflammation readout.
• Red flags — Fever, persistent injection site reaction, new swelling/lumps, unexplained bruising, any sign of concealed infection. Stop and evaluate.

Substitutions & Alternatives

• Downgrade to GLOW — Drop KPV. Simpler three-peptide skin/repair stack. Loses the specific NF-κB coverage; fewer variables to manage.
• Oral KPV alone — For pure gut inflammation goals (ulcerative colitis, Crohn's-adjacent symptoms, post-antibiotic gut inflammation), oral KPV alone can provide most of the anti-inflammatory benefit with a substantially simpler protocol than the full KLOW injected regimen.
• Swap KPV for TB-500 Fragment 17-23 (LKKTETQ) — Repair-focused fragment; less anti-inflammatory coverage.
• Add Thymosin α1 — For users where immune-balance rather than pure inflammation-suppression is the goal. Different mechanism; works well in users who are under-immunosuppressed (frequent infections) rather than over-inflamed.
• Add Larazotide for gut barrier — For users whose gut inflammation is tight-junction-mediated (leaky gut spectrum). Complementary to KPV's cytokine suppression.
• Replace with prescription biologics — For diagnosed IBD, psoriasis, rheumatoid arthritis, the evidence-based pathway is an approved biologic (anti-TNF, IL-17, IL-23). KLOW is not a substitute; it is an off-label adjunct at best.
• Low-FODMAP / elimination diet — Diet-mediated inflammation control often outperforms any peptide intervention. Don't skip the nutritional lever before escalating to injections.
• Omega-3, curcumin, vitamin D — Non-peptide anti-inflammatory adjuncts. Modest individual effects, additive, no injection burden.

Practical User Notes

• Don't start here — KLOW is a second or third protocol. Run Wolverine or GLOW first, understand your individual response to each leg, then add KPV if inflammation is the limiter.
• Add one thing at a time when possible — If you must add KPV to an existing GLOW cycle, add the oral KPV first for 2 weeks; confirm no adverse reactions; then add injected KPV or switch to KLOW blend.
• Oral KPV for gut, injected KLOW for systemic — KPV's PepT1-mediated oral bioavailability makes it unusual. Users running KLOW for IBD-spectrum goals often split: injected KLOW 3–5x/week for systemic coverage, plus oral KPV daily specifically for the gut leg.
• Blue solution test — Same as GLOW. Copper complex gives characteristic blue tint. Colorless KLOW solution is suspicious.
• Inflammation markers — hsCRP, ESR, and fecal calprotectin (if relevant) before/after. These numbers often change meaningfully on a successful KLOW cycle, which is useful objective feedback when the stack is doing something specific (beyond placebo).
• Don't run during active infection — NF-κB suppression during pneumonia or a severe UTI is actively counterproductive. Pause until resolved.
• Protein, sleep, sunscreen, stress — The fundamentals apply. KLOW is additive to an optimized baseline, not a rescue for a pro-inflammatory lifestyle.
• Alcohol, highly processed food, smoking — Antagonistic to every leg of the stack. Moderate during cycles.
• Source discipline — Four peptides means four chances for a bad product to ruin your cycle. Stick to a vendor with third-party COA for every compound. Pre-blend sourcing is higher-risk because you can't independently verify each component.
• Reassess by week 6 — If nothing is moving across any of the four axes, stop. Don't burn 12 weeks on a non-responsive cycle.
• Cycle discipline — 8–12 weeks on, 4 weeks off, not longer. KLOW is not a maintenance stack for continuous use.

Regulatory Status & Access

Bloodwork & Monitoring

Baseline and periodic labs for users on a 12-week KLOW cycle. This is observational best-practice, not validated monitoring. No formal clinical monitoring guideline exists for a four-peptide combination.

• Baseline CMP — Renal and hepatic function; electrolytes. Repeat at end of cycle.
• CBC — Standard baseline. Track for any unusual hematologic shifts.
• hsCRP — Baseline and end-of-cycle inflammation marker. A successful KLOW cycle in users with elevated baseline should see measurable hsCRP reduction if the anti-inflammatory mechanism is translating clinically.
• ESR — Complementary inflammation marker, particularly for MSK or rheumatologic overlays.
• Fecal calprotectin (IBD-spectrum users) — Objective colonic inflammation marker. Baseline and 8-week comparison is the most useful objective readout for gut-focused KLOW protocols.
• Serum ceruloplasmin + copper — For users on extended or repeat GHK-Cu-containing cycles (GLOW and KLOW). Copper overload is theoretical but testable.
• Ferritin — Iron status; commonly out-of-range in both IBD and chronic-inflammatory users.
• Vitamin D (25-OH) — Broad immune-modulation marker. Commonly low in inflammatory-skin and IBD populations.
• IgE (atopic context) — For users with atopic dermatitis or allergic skin conditions on KLOW for skin-inflammation goals.
• Symptom diary — Bristol stool scale and flare frequency for gut users; eczema severity index, itch scale, and standardized photos for skin users; VAS pain scale and range-of-motion for MSK users. Subjective recall is unreliable; structured tracking provides honest self-feedback.
• Red flags to stop — New fever, worsening infection signs, unexplained lumps, new bruising, persistent injection-site inflammation, new or worsening GI bleeding.

Practical User Notes

• Second or third protocol — Not a first protocol. Four variables is too many for a new user to attribute response or adverse reaction to the correct leg.
• Add one thing at a time when possible — If you are mid-cycle on GLOW and want to add KPV, add oral KPV first for two weeks as a compatibility test; convert to KLOW blend at the next cycle start.
• Oral KPV for gut, injected KLOW for systemic — The unusual PepT1-mediated oral bioavailability of KPV makes a dual-route strategy reasonable for gut-focused users. 200–500 mcg oral KPV 1–2x daily layered on top of 3–5x weekly injected KLOW blend.
• Blue solution test — Same as GLOW. GHK-Cu's copper complex produces a characteristic blue tint on reconstitution. A colorless KLOW solution is a sourcing red flag.
• Timing around the injection — Evening injection is most common — overlaps the sleep recovery window. Avoid pre-workout intense-training injections in users susceptible to injection-site reactions.
• Inflammation markers before and after — hsCRP, ESR, fecal calprotectin for gut users. Numbers moving in the right direction is the most honest signal that the stack is doing what you're paying for.
• Don't run during active infection — NF-κB suppression during pneumonia, severe UTI, or any systemic infection is actively counterproductive. Pause until resolved.
• Protein, sleep, sunscreen, stress — The fundamentals apply. KLOW is additive to an optimized baseline, not a rescue for a pro-inflammatory lifestyle.
• Alcohol, processed food, smoking — Antagonistic to every leg of the stack. Moderate during cycles; stop during the washout if possible.
• Source discipline — Four peptides is four chances for one bad product to ruin the cycle. Stick to a vendor with third-party HPLC/MS COAs for every compound. Pre-blend sourcing is higher-risk because you cannot independently verify each component.
• Reassess by week 6 — If nothing is moving across any of the four axes (inflammation, MSK, skin, gut), stop. Don't burn 12 weeks on a non-responsive cycle.
• Cycle discipline — 8–12 weeks on, 4 weeks off. KLOW is not a maintenance protocol for continuous use; chronic NF-κB suppression risks masking infection and over-suppressing useful inflammatory signaling.
• If you feel worse — Any persistent new symptom on an unapproved four-peptide stack is a cessation signal first, investigation signal second.
• Tracking photographic evidence — Standardized photographs at baseline and weeks 4, 8, and 12 are the most honest visual record for skin and scar responders. Same lighting, same angle, same time of day. Memory is unreliable; photos are not.
• Waist tape + bodyweight + sleep tracking — Non-photo objective signals that KLOW is shifting something. Waist-hip ratio and HRV trends on a wearable are better than subjective "feel" reports for tracking whether the stack is producing measurable downstream effect.
• Cost-benefit honesty — Four peptides costs more than three (GLOW). Users should weigh whether the added KPV leg is addressing a real inflammatory limiter or whether simpler interventions (dietary, sleep, sun-exposure, stress) would produce the same benefit without the injection complexity.
• Responder profiles — Based on aggregated community experience, the clearest responders to KLOW over GLOW alone are users with chronic inflammatory skin conditions (atopic dermatitis, chronic rosacea), IBD-spectrum gut symptoms overlapping MSK injury, post-viral chronic inflammation (post-COVID, post-EBV), and users with measurably elevated baseline hsCRP or ESR. Users with no inflammatory overlay typically do not see added benefit over GLOW.

Related Compounds

People researching the KLOW Stack often also look at these:

Next Steps

References

No clinical trial has studied the four-peptide KLOW combination in humans. References below cover the individual components and the mechanistic framework.

1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520.
2. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex. FEBS Lett. 1988;238(2):343-346. PMID: 3169264.
3. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. PMID: 21548867.
4. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 2003;21(6):976-983. PMID: 14554208.
5. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4. Proc Natl Acad Sci USA. 1981;78(2):1162-1166. PMID: 6940133.
6. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration. Nature. 2004;432(7016):466-472. PMID: 15565145.
7. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID: 18061177.
8. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PMID: 18092346.
9. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-MSH and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo. Endocr Rev. 2008;29(5):581-602. PMID: 18490917.
10. Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004;56(1):1-29. PMID: 15001661.
11. FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) — 503A / 503B. FDA.gov, updated 2025.
12. WADA. 2025 Prohibited List. Sections S0 and S2. World Anti-Doping Agency.

→ Use the Kalios Peptide Calculator for exact syringe units